Medical device are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity par
Medical device are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is water-soluble. In further embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has a molecular weight of from 80 to 750 or has more than four hydroxyl groups.
대표청구항▼
1. A balloon catheter for delivering a therapeutic agent to a target site of a body lumen chosen from an esophagus, an airway, a sinus, a trachea, a colon, a biliary tract, a urinary tract, or a prostate, the balloon catheter comprising a balloon and a coating layer overlying external surfaces of th
1. A balloon catheter for delivering a therapeutic agent to a target site of a body lumen chosen from an esophagus, an airway, a sinus, a trachea, a colon, a biliary tract, a urinary tract, or a prostate, the balloon catheter comprising a balloon and a coating layer overlying external surfaces of the balloon, wherein: the coating layer consists essentially of a water-soluble first additive, a water soluble second additive, and a hydrophobic therapeutic agent;the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, everolimus, docetaxel, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, and combinations thereof;the water-soluble first additive is selected from the group consisting of gluconolactone, PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, and PEG sorbitan palmitates; andthe water-soluble second additive is selected from the group consisting of sorbitol, sorbitan, xylitol, lactobionic acid, and combinations thereof. 2. The balloon catheter of claim 1, wherein the water-soluble first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, and PEG-20 sorbitan monooleate. 3. The balloon catheter of claim 1, wherein: the hydrophobic therapeutic agent is paclitaxel; andthe water-soluble first additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate. 4. The balloon catheter of claim 1, wherein: the hydrophobic therapeutic agent is paclitaxel; andthe water-soluble first additive is gluconolactone. 5. The balloon catheter of claim 1, wherein: the water-soluble first additive is selected from the group consisting of PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, and PEG sorbitan palmitates. 6. The balloon catheter of claim 5, wherein: the hydrophobic therapeutic agent is paclitaxel; andthe water-soluble first additive is PEG-20 sorbitan monooleate; andthe water-soluble second additive is sorbitol. 7. A method for treating a diseased body lumen, the method comprising: inserting a balloon catheter into a diseased body lumen to a target site in the diseased body lumen, the diseased body lumen chosen from an esophagus, an airway, a sinus, a trachea, a colon, a biliary tract, a urinary tract, or a prostate, the balloon catheter comprising a balloon and a coating layer overlying external surfaces of the balloon, wherein: the coating layer consists essentially of a water-soluble first additive, a water soluble second additive, and a hydrophobic therapeutic agent;the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, everolimus, docetaxel, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, and combinations thereof; andthe water-soluble first additive is selected from the group consisting of gluconolactone, PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, and PEG sorbitan palmitates; andthe water-soluble second additive is selected from the group consisting of sorbitol, sorbitan, xylitol, lactobionic acid, and combinations thereof;inflating the balloon catheter until the coating layer contacts walls of the diseased body lumen at the target site and releases therapeutic agent to the walls of the diseased body lumen;deflating the balloon catheter; andwithdrawing the balloon catheter from the diseased body lumen. 8. The method of claim 7, wherein the diseased body lumen is a urinary tract. 9. The method of claim 8, wherein: the hydrophobic therapeutic agent is paclitaxel; andthe water-soluble first additive is gluconolactone. 10. The method of claim 8, wherein: the water-soluble first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, and PEG-20 sorbitan monooleate. 11. The method of claim 8, wherein: the hydrophobic therapeutic agent is paclitaxel; andthe water-soluble first additive is PEG-20 sorbitan monooleate; andthe water-soluble second additive is sorbitol. 12. The method of claim 7, wherein the diseased body lumen is a lumen of a prostate. 13. The method of claim 12, wherein: the hydrophobic therapeutic agent is paclitaxel; andthe water-soluble first additive is gluconolactone. 14. The method of claim 12, wherein: the water-soluble first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, and PEG-20 sorbitan monooleate. 15. The method of claim 12, wherein: the hydrophobic therapeutic agent is paclitaxel; andthe water-soluble first additive is PEG-20 sorbitan monooleate; andthe water-soluble second additive is sorbitol. 16. The method of claim 7, wherein the diseased body lumen is an airway or a sinus. 17. The method of claim 16, wherein: the hydrophobic therapeutic agent is paclitaxel; andthe water-soluble first additive is gluconolactone. 18. The method of claim 16, wherein: the water-soluble first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, and PEG-20 sorbitan monooleate. 19. The method of claim 16, wherein: the hydrophobic therapeutic agent is paclitaxel; andthe water-soluble first additive is PEG-20 sorbitan monooleate; andthe water-soluble second additive is sorbitol.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (255)
Caufield Craig E. (Princeton Junction NJ) Grinfeld Alexander A. (Princeton Junction NJ), 42-Epi-rapamycin and pharmaceutical compositions thereof.
Osbakken, Robert S.; Hale, Mary Anne; Leivo, Frederick T.; Munk, James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Daniel Castro ; Steven Wu ; Kevin L. Woolbright ; Kurt W. Scheinpflug ; Syed F. A. Hossainy ; Li Chen, Apparatus and method for depositing a coating onto a surface of a prosthesis.
Slepian Marvin J. (Cleveland Heights OH) Schindler Anton (Durham NC), Biodegradable polymeric endoluminal sealing process, apparatus and polymeric product for use therein.
Molnar-Kimber Katherine L. (Glenside PA) Ocain Timothy D. (Waltham MA) Vernon Steven K. (Havertown PA) Huang John J. (San Carlos CA), Biotin esters of rapamycin.
Solomon Donald D. (Spring Valley OH) Taller Robert A. (Centerville OH) Williamitis Victor A. (Dayton OH), Blood compatible, lubricious article and composition and method therefor.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Kao Wenling (Paoli PA) Skotnicki Jerauld S. (Allentown NJ) Abou-Gharbia Magid A. (Glen Mills PA) Palmer Yvette L. (Newtown PA), Carbamates of rapamycin.
Skotnicki Jerauld S. (Allentown NJ) Palmer Yvette L. (Newtown PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapaycin.
Bacher Peter (Nurnberg DEX) Walenga Jeanine M. (Lombard IL), Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities.
Fearnot Neal E. (West Lafayette IN) Kozma Thomas G. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees William D. (West Lafayette IN), Coated implantable medical device.
Ragheb, Anthony O.; Bates, Brian L.; Fearnot, Neal E.; Kozma, Thomas G.; Voorhees, III, William D.; Gershlick, Anthony H., Coated implantable medical device.
Amundson Rodney R. (Lindstrom MN) Hull Vincent W. (Ham Lake MN) Dror Michael (Edina MN) Schwartz Robert S. (Rochester MN), Drug delivery balloon catheter with line of weakness.
Fitzhugh,Anthony L.; Cafferata,Robert; Keefer,Larry K., Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use.
Reiley Mark A. ; Scholten Arie ; Talmadge Karen D., Inflatable device for use in surgical protocols relating to treatment of fractured or diseased bones.
Armstrong Jay J. (Bensalem PA) Sehgal Surendra N. (Princeton NJ), Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements.
Bucay-Couto, Weenna; Li, Jamie (Jianmin), Long-term indwelling medical devices containing slow-releasing antimicrobial agents and having a surfactant surface.
Skotnicki Jerauld S. (Allentown NJ) Failli Amedeo A. (Princeton Junction NJ) Steffan Robert J. (Langhorne NJ) Kearney Robert M. (Lawrenceville NJ), Macrocyclic immunomodulators.
Hostettler Fritz ; Rhum David ; Forman Michael R. ; Helmus Michael N. ; Ding Ni, Medical device coated with interpenetrating network of hydrogel polymers.
Rosen Gerald M. ; Herzog ; Jr. William R. ; Pou Sovitj, Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosy.
Fan You-Ling (East Brunswick NJ) Marlin Lawrence (Bridgewater NJ) Sahatjian Ronald A. (Lexington MA) Schultz Steven A. (Northboro MA), Medical device with lubricious coating.
Amundson Rodney R. (Lindstrom MN) Hull Vincent W. (Ham Lake MN) Dror Michael (Edina MN) Schwartz Robert S. (Rochester MN), Method for making a drug delivery balloon catheter.
Zhong Sheng-Ping (Farum DKX), Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with s.
Kinsella James L. (Baltimore MD) Sollott Steven J. (Baltimore MD), Method of treating atherosclerosis or restenosis using microtubule stabilizing agent.
Wang, Jeffrey; Malinoff, Harrison; Wang, Lixiao; Barry, Christopher M.; Wahr, Dennis W.; Naisbitt, Scott R., Methods and apparatuses for coating balloon catheters.
Conway Anthony J. (Chatfield MN) Conway Philip J. (Chatfield MN) Fryar ; Jr. Richard D. (Rochester MN), Microcidal agent releasing catheter with balloon.
Roorda,Wouter E.; Ding,Ni; Pacetti,Stephen D.; Michal,Eugene T.; Shah,Ashok A.; Hossainy,Syed F. A., Polyacrylates coatings for implantable medical devices.
Failli Amedeo (Princeton Junction NJ) Kao Wenling (Paoli PA) Steffan Robert J. (Langhorne PA) Vogel Robert L. (Stratford NJ), Rapamycin 42-sulfonates and 42-(N-carbalkoxy) sulfamates useful as immunosuppressive agents.
Failli Amedeo A. (Princeton Junction NJ) Kao Wenling (Paoli PA) Steffan Robert J. (Langhorne PA) Vogel Robert L. (Stratford NJ), Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents.
Sehgal Surendra N. (Dollard des Ormeaux CA) Blazekovic Teodora M. (Mount Royal CA) Vezina Claude (Deux-Montagnes CA), Rapamycin and process of preparation.
Harrison Maureen M. (St. Albans VT) Ofslager Christian L. (Plattsburgh NY) Waranis Robert P. (Chazy NY) Leonard Thomas W. (Wilmington NC), Rapamycin formulations for oral administration.
Failli Amedeo A. (Princeton Junction NJ) Steffan Robert J. (Langhorne PA) Caufield Craig E. (Princeton Junction NJ) Hu David C. (Langhorne PA) Grinfeld Alexander A. (Princeton Junction NJ), Rapamycin oximes.
Failli Amedeo A. (Princeton Junction NJ) Steffan Robert J. (Langhorne PA) Caufield Craig E. (Princeton Junction NJ) Hu David C. (Langhorne PA) Grinfeld Alexander A. (Princeton Junction NJ), Rapamycin oximes.
Kao Wenling (Paoli PA) Vogel Robert L. (Stratford NJ) Abou-Gharbia Magid A. (Glen Mills PA) Caufield Craig E. (Princeton Junction NJ), Rapamycin oximes and hydrazones.
Roorda,Wouter E.; Hossainy,Syed F. A.; Ding,Ni; Tang,Fuh Wei; Pacetti,Stephen D., Rate limiting barriers for implantable devices and methods for fabrication thereof.
Gregory T. Sydney ; Russ Seiber ; Arthur R. Madenjian ; Annette Belovi, Selective coating of a balloon catheter with lubricious material for stent deployment.
Sydney Gregory T. ; Seiber Russ ; Madenjian Arthur R. ; Belovi Annette, Selective coating of a balloon catheter with lubricious material for stent deployment.
Ragheb Anthony O. ; Bates Brian L. ; Fearnot Neal E. ; Osborne Thomas A. ; Kozma Thomas G. ; Roberts Joseph W. ; Voorhees ; III William D., Silver implantable medical device.
Hostettler Fritz ; Rhum David ; Forman Michael R. ; Helmus Michael N. ; Ding Ni, Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a pol.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GB2 ; Metcalfe James C.,GB2 ; Weissberg Peter L.,GB2 ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Fearnot Neal E. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees ; III William D. (West Lafayette IN), Thrombolytic treated intravascular medical device.
Nilsson Bo (Helsingborg SEX) Kalland Terje (Lddekpinge SEX) Termander Birgitta (Helsingborg SEX), Use of Linomide to increase hemopoietic cell precursors.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.